Search

Displaying results 2501 - 2510 of 10000 in total
  1. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    [A261826] In fact, it has been observed that antigen-activated T cells within peripheral lymphoid organs can transiently downregulate S1P receptor levels to facilitate immune cells trafficking into the … [A261826] Therefore, S1P receptor modulators like etrasimod were investigated in treating immune-mediated diseases like ulcerative colitis where a high level of inflammatory T cells is present in the gastrointestinal

    Categories: Sphingosine-1-phosphate (S1P) receptor modulators
  2. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.

    Categories: Epidermal Growth Factor Receptor Antagonist, EGFR (Epidermal Growth Factor Receptor) inhibitors
  3. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    (NMDA) receptor,[A18263] indicating a role for the glutamatergic system in the pathophysiology of ADHD. … The non-stimulant norepinephrine/dopamine reuptake inhibitor [DB01156] (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of

  4. Target

    P2X purinoceptor 7

    go.drugbank.com/bio_entities/BE0009814
    TargetHumans

    ATP-gated nonselective transmembrane cation channel that requires high millimolar concentrations of ATP for activation (PubMed:17483156, PubMed:25281740, PubMed:9038151). Upon ATP binding, it rapidly opens to allow the influx of small ca...

    Synonyms: ATP receptor, P2Z receptor
  5. Drug

    Trichlormethiazide

    go.drugbank.com/drugs/DB01021
    ApprovedVet approved

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

  6. Drug

    Potassium bicarbonate

    go.drugbank.com/drugs/DB11098
    ApprovedInvestigational

    [T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for OTC antacids.[L1836] This FDA denomination classifies potassium bicarbonate as a GRAS ingredient. … It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid.

  7. Drug

    Sertraline

    go.drugbank.com/drugs/DB01104
    ApprovedInvestigational

    Several weeks of therapy with sertraline may be required before beneficial effects are noticed. … Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    Unlike traditional statin therapy, which relies on the upregulation of LDL receptors to clear cholesterol, Lomitapide acts independently of the LDL receptor by preventing the assembly and secretion of … [A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity.

  9. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    binding at the ATP domain of the epidermal growth factor receptor family kinase domains. … [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  10. Drug

    Sebetralstat

    go.drugbank.com/drugs/DB18305
    ApprovedInvestigational

    This plasma kallikrein inhibitor works by reducing bradykinin, the substance that causes the characteristic swelling in HAE attacks [L53533]. The U.S. … Sebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293].